𝔖 Bobbio Scriptorium

✦ LIBER ✦

Survival ASCENT with calcitriol + docetaxel for prostate cancer

Book ID: 120848100
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2007
Weight: 120 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200715790-00020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Calcitriol + docetaxel shows promise in

Calcitriol + docetaxel shows promise in prostate cancer

📂 Article 📅 2003 🏛 Adis International Limited (now part of Wolters Kl ⚖ 138 KB

Weekly high-dose calcitriol and docetaxe

Weekly high-dose calcitriol and docetaxel in advanced prostate cancer

✍ Tomasz M Beer; Kristine M Hough; Mark Garzotto; Bruce A Lowe; W.David Henner 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 756 KB

ASCENT: The androgen-independent prostat

ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere

✍ Tomasz M. Beer 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

Double-Blinded Randomized Study of High-

Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators

✍ Kibel, A.S. 📂 Article 📅 2008 🏛 Elsevier Science ⚖ 55 KB

Double-Blinded Randomized Study of High-

Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators

✍ Andriole, G.L. 📂 Article 📅 2007 🏛 Elsevier Science ⚖ 63 KB

Intermittent chemotherapy in patients wi

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer : Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel

✍ Tomasz M. Beer; Christopher W. Ryan; Peter M. Venner; Daniel P. Petrylak; Gurkam 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

## Abstract ## BACKGROUND. Survival in patients with metastatic, chemotherapy‐naive, androgen‐independent prostate cancer (AIPC) is improved with 10 to 12 cycles of docetaxel‐containing chemotherapy but further management is undefined. In the current study, the authors examined retreatment with th